Stoke Therapeutics Cash Flow Statement

Financials in millions USD. Fiscal year is January - December.

Millions USD. Fiscal year is Jan - Dec.

Fiscal Year	TTM	FY 2024	FY 2023	FY 2022	FY 2021	FY 2020
Period Ending	Sep '25 Sep 30, 2025	Dec '24 Dec 31, 2024	Dec '23 Dec 31, 2023	Dec '22 Dec 31, 2022	Dec '21 Dec 31, 2021	Dec '20 Dec 31, 2020
Net Income	40.57	-88.98	-104.7	-101.07	-85.81	-52.24
Depreciation & Amortization	1.89	2.18	2.47	1.55	0.97	0.89
Loss (Gain) From Sale of Assets	-0.01	-	0	-	0.03	0
Loss (Gain) From Sale of Investments	-1.36	-1.64	-0.33	-0.21	0.14	-
Stock-Based Compensation	29.53	27.47	25.26	22.85	16.45	5.77
Other Operating Activities	2.34	2.27	2.26	1.99	1.26	1.04
Change in Accounts Payable	14.57	3.09	-3.21	-3.53	2.9	5.2
Change in Unearned Revenue	-25.58	-29.39	-3.35	51.74	-	-
Change in Other Net Operating Assets	-2.56	-1.84	0.53	-5.18	-2.85	-2.88
Operating Cash Flow	52.85	-86.85	-81.07	-31.87	-66.91	-42.22
Capital Expenditures	-0.48	-0.2	-1.62	-3.96	-1.2	-1.05
Investment in Securities	-124.45	-107.27	107.56	-41.92	-75.23	-
Investing Cash Flow	-124.93	-107.48	105.95	-45.88	-76.43	-1.05
Issuance of Common Stock	5.62	131.09	53.01	46.41	1.29	108.59
Other Financing Activities	-	-	-	0	-0	-0.49
Financing Cash Flow	5.62	131.09	53.01	46.41	1.28	108.11
Net Cash Flow	-66.47	-63.23	77.89	-31.34	-142.05	64.84
Free Cash Flow	52.37	-87.05	-82.68	-35.83	-68.11	-43.27
Free Cash Flow Margin	25.47%	-238.15%	-941.72%	-288.82%	-	-
Free Cash Flow Per Share	0.88	-1.61	-1.88	-0.92	-1.85	-1.29
Levered Free Cash Flow	29.57	-26.45	-45.07	-36.15	-34.78	-24.35
Unlevered Free Cash Flow	29.57	-26.45	-45.07	-36.15	-34.78	-24.35
Change in Working Capital	-20.81	-28.14	-6.03	43.02	0.05	2.33

Source: S&P Global Market Intelligence. Standard template. Financial Sources.